Introduction: The treatment of penile cancer has changed over the past decade in that it was primarily a surgically managed disease and those with locally advanced or metastatic disease uniformly had a very poor prognosis.
However, with the use of better traditional systemic chemotherapeutic agents in the neoadjuvant and adjuvant settings, the disease-specific survival and general outlook has improved. However, there is still a large group of patients who will progress even while on systemic therapy. It is in those patients where the application of targeted therapies has been investigated with some experiencing partial or even complete responses. With the improvement seen in patients with chemotherapy refractory disease, the application of novel targeted agents in the neoadjuvant setting may have a resultant positive impact on patient survival.
Areas covered: This review includes research pertaining to targeted therapies, biomarkers and signaling pathways involved with penile cancer. The article was based on a literature search using the keywords 'penile cancer' and 'targeted therapies'.
Expert opinion: Penile cancer at the advanced stages of the disease has a high mortality. The utilization of novel targeted therapies in these situations is warranted in combination with, or sequentially with, traditional cytotoxic chemotherapy to improve the patient survival rate. Personalized therapy is nearly here for penile cancer and should be made real within the next decade.
Written by:
Agarwal G, Gupta S, Spiess PE. Are you the author?
Moffitt Cancer Center, Department of Genitourinary Oncology, Tampa, FL, USA.
Reference: Expert Opin Drug Discov. 2014 Jun 4:1-10.
doi: 10.1517/17460441.2014.925875
PubMed Abstract
PMID: 24896220
UroToday.com Penile and Urethral Cancers Section
